 Carfilzomib also known as Kyprolis is an anti-cancer drug classified as a selective proteasome inhibitor. Proteasome inhibition affects the levels of numerous cell cycle control proteins, apoptosis i.e., cell death, cell adhesion, angiogenesis, and chemoresistance proteins. Chemically, it is a tetrapeptide epoxyketone, similar to epoxomicin. 